Doctors could soon
have a new range of drugs to use in their treatment of ovarian cancer patients.
Scientists working at the Oregon Health & Science University Knight
Cancer Institute may have made a major breakthrough in their efforts to
understand a group of defective proteins that inhibit the body's ability to
repair its own DNA.
It is believed that poly ADP ribose polymerase (PARP) inhibitors could be
crucial to stopping the growth of some types of the cancer and are now being
tested on patients with malfunctioning proteins.
"If we are able to identify the proteins that differentiate these patients
at risk for early recurrence, this would open up a new direction in ovarian
cancer treatment," said Tanja Pejovic, who led the study.
According to Cancer Research UK, 40 per cent of women who develop ovarian
cancer currently survive for at least five years, with survival rates
increasing when the disease is diagnosed in the early stages.
© Adfero Ltd
Cancer treatment news : 19 January 2012